News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Optical Sensors To Do Business As VASAMED (OPSI)


10/19/2005 5:11:18 PM

MINNEAPOLIS, May 17 /PRNewswire/ -- Optical Sensors Inc. (BULLETIN BOARD: OPTL) ("OSI"), developer and supplier of hemodynamic monitoring solutions, today announced that it would begin doing business as VASAMED.

"The name 'VASAMED' underscores our express mission to provide non- invasive diagnostic tools for a variety of conditions, all of which involve blood flow and perfusion," stated Paulita LaPlante, president and chief executive officer. "It better reflects the suite of products that we currently have and will be introducing for hemodynamic monitoring. Five years ago, we embarked on a deliberate process of re-defining our corporate mission and strategic direction. Secondary to re-capitalizing our company, we executed a key license and royalty agreement with Nellcor, acquired two product lines and key technology and added ten U.S. patents to our growing intellectual property portfolio which now stands at forty issued U.S. patents. The use of the name VASAMED completes this process and allows our company to go into the next five years with a coherent strategy that focuses us on sales into the burgeoning office-based diagnostic business with an array of vascular product solutions."

VASAMED is a technology development company specializing in low-cost, non- invasive vascular diagnostic systems for non-invasive hemodynamic monitoring. Products developed by VASAMED include the CapnoProbe(TM) sensor system for the measurement of sublingual CO2. VASAMED licensed an application of CapnoProbe technology to Nellcor in 2001 which has positioned the product as an early warning signal of tissue hypoperfusion and possible organ failure. VASAMED manufactures and supplies LASERDOPP PV2000, a skin perfusion pressure and pulse volume waveform diagnostic for quantitative evaluation of small vessel disease in patients with chronic foot ulcers, diabetes and other peripheral arterial disease. Skin perfusion pressures are not affected by edema, anemia, medial calcification or certain other conditions that limit the usefulness of other measurement technologies.

For more information about VASAMED technology and services, see the company's web sites at http://www.opsi.com/ and at http://www.vasamedics.com/ . For more information about Nellcor(R) CapnoProbe(TM) Sublingual (SL) System, see http://www.nellcor.com/ .

Optical Sensors

CONTACT: Wes Peterson, CFO, of Optical Sensors, +1-952-944-5857,ext. 542


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES